Ordinarily, Tagline doesn’t track drug developments, but rather follows devices and process technologies.  But a recent special report in Genetic Engineering and Biotechnology News has an excellent piece on “the Future of Ocular Therapeutics” that’s worth mentioning as it discusses the subclassification of eye diseases where automated solutions may also find opportunities.       MORE